Aethlon Medical Reports $1.76 Million Net Loss, Focuses on Hemopurifier Clinical Trials

Aethlon Medical, Inc. reported a net loss of $1.76 million for the three months ended June 30, 2025, a decrease from a net loss of $2.57 million during the same period in 2024. The company's basic and diluted loss per share improved to $(0.85) from $(2.76) year-over-year. Total operating expenses for the quarter were $1.79 million, down 31.6% from $2.62 million in the prior year, primarily due to reductions in payroll and related expenses, professional fees, and general administrative costs. The company’s cash and cash equivalents decreased to $3.77 million from $5.50 million at the end of the previous fiscal quarter, reflecting ongoing operational expenditures.

In terms of operational developments, Aethlon Medical is focused on its Hemopurifier® device, which is currently undergoing clinical trials in Australia for oncology applications. The company has treated three participants in its phase 1 trial, with no reported serious adverse events. Aethlon has also received regulatory approval to conduct a similar trial in India but has decided to cancel this initiative to concentrate resources on the Australian trial. The company is exploring additional applications for the Hemopurifier, including potential uses in treating Long COVID and other diseases.

The company’s total liabilities decreased to $1.88 million as of June 30, 2025, from $2.24 million at the end of March 2025. This reduction was attributed to lower accounts payable and amounts due to related parties. Aethlon's stockholders' equity also declined to $3.42 million from $5.12 million, primarily due to the net loss incurred during the quarter. The company’s employee headcount has been reduced, contributing to lower payroll expenses, which were down by approximately $673,802 compared to the previous year.

Looking ahead, Aethlon Medical acknowledges that its existing cash reserves may not be sufficient to fund operations for the next twelve months, raising concerns about its ability to continue as a going concern. The company is actively evaluating various strategic and financing options to extend its cash runway, including potential equity offerings. However, there is no assurance that such financing will be available on favorable terms. The company is also monitoring external factors such as inflation and geopolitical events that could impact its operations and access to capital.